Mild Cognitive Impairment Pipeline Guide, H1 2020 – Therapeutics Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type

DUBLIN, April 22, 2020 /PRNewswire/ — The “Mild Cognitive Impairment – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This Pharmaceutical and Healthcare pipeline guide, Mild Cognitive Impairment – Pipeline Review, H1 2020 provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 3, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

• Introduction
• Mild Cognitive Impairment – Overview
• Mild Cognitive Impairment – Therapeutics Development
• Mild Cognitive Impairment – Therapeutics Assessment
• Mild Cognitive Impairment – Companies Involved in Therapeutics Development
• Mild Cognitive Impairment – Drug Profiles
• Mild Cognitive Impairment – Dormant Projects
• Mild Cognitive Impairment – Discontinued Products
• Mild Cognitive Impairment – Product Development Milestones
• Appendix

• Companies Mentioned

  • Addex Therapeutics Ltd
  • AgeneBio Inc
  • Avraham Pharmaceuticals Ltd
  • Cerebrum Therapeutics Inc
  • CereSpir Inc
  • CuraSen Therapeutics Inc
  • Eli Lilly and Co
  • Fujifilm Toyama Chemical Co Ltd
  • Grespo AB
  • ImmunoChem Therapeutics LLC
  • IntelGenx Corp
  • INVENT Pharmaceuticals Inc
  • Merck & Co Inc
  • NeurAegis Inc
  • NeuroActiva Inc
  • Neuron Biopharma SA
  • NLS Pharma Group
  • Octapharma AG
  • Partner Therapeutics Inc
  • Pfizer Inc
  • ProNeurogen Inc
  • Protekt Therapeutics Ltd
  • Sage Therapeutics Inc
  • SBI Pharmaceuticals Co Ltd
  • Therapix Biosciences Ltd

  For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p0g01g

  Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

  Media Contact:

  Research and Markets
  Laura Wood, Senior Manager
  press@researchandmarkets.com   

  For E.S.T Office Hours Call +1-917-300-0470
  For U.S./CAN Toll Free Call +1-800-526-8630
  For GMT Office Hours Call +353-1-416-8900

  U.S. Fax: 646-607-1904
  Fax (outside U.S.): +353-1-481-1716

  View original content:https://www.prnewswire.com/news-releases/mild-cognitive-impairment-pipeline-guide-h1-2020—therapeutics-analysis-by-stage-of-development-drug-target-mechanism-of-action-route-of-administration-and-molecule-type-301045315.html

  SOURCE Research and Markets

April 23, 2020